IN2012DN00858A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00858A
IN2012DN00858A IN858DEN2012A IN2012DN00858A IN 2012DN00858 A IN2012DN00858 A IN 2012DN00858A IN 858DEN2012 A IN858DEN2012 A IN 858DEN2012A IN 2012DN00858 A IN2012DN00858 A IN 2012DN00858A
Authority
IN
India
Prior art keywords
propionamide
thiazol
pyrrolidin
methylamino
benzoyl
Prior art date
Application number
Other languages
English (en)
Inventor
Jeewan Thakur
Dong Yang
Lili Feng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00858(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2012DN00858A publication Critical patent/IN2012DN00858A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN858DEN2012 2009-08-12 2010-08-11 IN2012DN00858A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27405109P 2009-08-12 2009-08-12
PCT/EP2010/061679 WO2011018474A1 (en) 2009-08-12 2010-08-11 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein

Publications (1)

Publication Number Publication Date
IN2012DN00858A true IN2012DN00858A (sl) 2015-07-10

Family

ID=42937834

Family Applications (1)

Application Number Title Priority Date Filing Date
IN858DEN2012 IN2012DN00858A (sl) 2009-08-12 2010-08-11

Country Status (24)

Country Link
US (4) US8623385B2 (sl)
EP (1) EP2464644A1 (sl)
JP (3) JP2013501751A (sl)
KR (2) KR20120048008A (sl)
CN (2) CN105646471A (sl)
AR (1) AR077869A1 (sl)
AU (4) AU2010283748A1 (sl)
BR (1) BR112012003118A2 (sl)
CA (1) CA2769616A1 (sl)
CL (1) CL2012000349A1 (sl)
CO (1) CO6612189A2 (sl)
IL (1) IL217760A0 (sl)
IN (1) IN2012DN00858A (sl)
MA (1) MA33511B1 (sl)
MX (2) MX2012001844A (sl)
MY (1) MY160475A (sl)
PE (2) PE20121132A1 (sl)
PH (1) PH12014501890A1 (sl)
RU (1) RU2671196C1 (sl)
SG (1) SG177713A1 (sl)
TN (1) TN2012000026A1 (sl)
TW (1) TWI607006B (sl)
WO (1) WO2011018474A1 (sl)
ZA (1) ZA201200390B (sl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019514878A (ja) 2016-04-20 2019-06-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Ripk2阻害剤を含むコンジュゲート
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119060A1 (en) 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2004005248A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ME02125B (me) * 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
EA019420B1 (ru) * 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
PE20110218A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
BR112012003118A2 (pt) 2016-02-23
RU2012108931A (ru) 2013-09-27
US20140093570A1 (en) 2014-04-03
PH12014501890B1 (en) 2015-09-14
MA33511B1 (fr) 2012-08-01
US20180370960A1 (en) 2018-12-27
MY160475A (en) 2017-03-15
AU2010283748A1 (en) 2012-02-09
CA2769616A1 (en) 2011-02-17
US8623385B2 (en) 2014-01-07
CN105646471A (zh) 2016-06-08
TN2012000026A1 (en) 2013-09-19
WO2011018474A8 (en) 2011-09-22
TWI607006B (zh) 2017-12-01
JP2016179976A (ja) 2016-10-13
US9540363B2 (en) 2017-01-10
CN102471331A (zh) 2012-05-23
MX2012001844A (es) 2012-02-29
EP2464644A1 (en) 2012-06-20
US10093665B2 (en) 2018-10-09
US20170081319A1 (en) 2017-03-23
WO2011018474A1 (en) 2011-02-17
MX351274B (es) 2017-10-06
RU2671196C1 (ru) 2018-10-30
KR20120048008A (ko) 2012-05-14
AU2016203145A1 (en) 2016-06-02
AU2014213533A1 (en) 2014-09-04
ZA201200390B (en) 2012-10-31
CO6612189A2 (es) 2013-02-01
PE20121132A1 (es) 2012-09-04
AU2017254950A1 (en) 2017-11-23
JP2013501751A (ja) 2013-01-17
AR077869A1 (es) 2011-09-28
KR20180020315A (ko) 2018-02-27
JP2018172403A (ja) 2018-11-08
CL2012000349A1 (es) 2012-09-07
PH12014501890A1 (en) 2015-09-14
SG177713A1 (en) 2012-02-28
CN102471331B (zh) 2016-01-13
AU2017254950B2 (en) 2018-09-20
TW201118091A (en) 2011-06-01
US20120128742A1 (en) 2012-05-24
IL217760A0 (en) 2012-03-29
PE20170777A1 (es) 2017-07-04

Similar Documents

Publication Publication Date Title
EP2477625A4 (en) PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS COMPRISING PLECKSTRINE HOMOLOGY DOMAIN INHIBITORS AND METHODS OF USE
IL231079A (en) Intermediate Compounds for Preparing –1– (s) - n– (s) Cyclohexyl – 22– (s)} - - {4– [4-Fluoro-benzoyl) -thiazole-2-yl] -pyralidine-1-yl} (2-oxo-ethyl) -2-methylamino-propionamide
UA105911C2 (uk) Сульфонамідні похідні
MX2010003866A (es) Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
MX2011003473A (es) Composiciones para el cuidado bucal.
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
TR201903195T4 (tr) Apiksaban formülasyonları.
WO2013072932A3 (en) Oral care compositions
MY150855A (en) Oral compositions containing extracts of zizyphus joazeiro and related methods
IN2012DN01233A (sl)
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2011011109A (es) Formulaciones orales de bendamustina.
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
TN2010000299A1 (en) Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydropy-ran-4-yl)-propionamide
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
MX2010005714A (es) Compuestos de piridina.
IN2012DN01232A (sl)
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
ECSP12011659A (es) Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
PH12014501890A1 (en) Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein